Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Microbiology

Vol 9 No 2 (2024): December

Unmasking Hidden Threats Global Spread of MBL Resistance Exposed
Membuka Kedok Ancaman Tersembunyi Penyebaran Global Resistensi MBL yang Terekspos



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.8994
Published
May 17, 2024

Abstract

This study aims to establish a routine monitoring system for MBL enzymes to provide timely data to healthcare professionals and policy makers, enabling informed decision making on antibiotic use and resistance management. Using a combination of molecular biology techniques and data analysis, we monitor MBL activity in various institutional settings. The increasing prevalence of multidrug-resistant (MDR) bacteria is a significant threat to public health globally. Metallo-beta-lactamase (MBL), an enzyme that confers resistance to a wide range of beta-lactam antibiotics, is particularly concerning due to its ability to spread rapidly in healthcare and community settings. Despite the importance of this issue, systematic monitoring and understanding of MBL remains inadequate. Our findings reveal a significant, previously unreported presence of MBLs, underscoring the urgent need for targeted antibiotic stewardship programs. The implications of this study emphasize the importance of integrating enzyme monitoring into standard healthcare practices to reduce the spread of MDR bacteria.   Highlights:
  • Regular Monitoring: Essential for tracking MBL enzyme prevalence and guiding antibiotic use.
  • Advanced Techniques: Molecular biology methods enhance MBL detection and analysis.
  • Policy Integration: Crucial for implementing enzyme monitoring in healthcare to combat MDR bacteria spread.

Keywords: MBL Enzymes, Antibiotic Resistance, Healthcare Monitoring, Molecular Biology, Stewardship Programs

References

  1. F. M. Abbas, "Metallo-Beta-Lactamases: A Review," Annals of R.S.C., vol. 25, no. 5, pp. 1308, 2021. Available: https://www.researchgate.net/publication/351286854
  2. S. B. Almasaudi, "Acinetobacter spp. as Nosocomial Pathogens: Epidemiology and Resistance Features," Saudi J. Biol. Sci., vol. 25, no. 3, pp. 586-596, 2018.
  3. N. T. Antunes and J. F. Fisher, "Acquired Class D Beta-Lactamases," Antibiotics (Basel), vol. 3, pp. 398-434, 2014. https://doi.org/10.3390/antibiotics3030398
  4. Z. M. E. Al-lamy, "Detection of ESBLs in Klebsiella spp. Isolated from Clinical and Environmental Samples at Thi-Qar Province," Master Thesis, Thi-Qar University, Iraq, 2016.
  5. L. Balsalobre, A. Blanco, and T. Alarcón, "Beta-Lactams," in Antibiotic Drug Resistance, J-L. Capelo-Martinez and G. Igrejas, Eds., John Wiley & Sons Inc., pp. 183, 2020.
  6. E. Bettiol and S. Harbarth, "Development of New Antibiotics: Taking Off Finally?" Swiss Med Wkly, vol. 145, w14167, 2015.
  7. E. R. Bevan, A. M. Jones, and P. M. Hawkey, "Global Epidemiology of CTX-M Beta-Lactamases: Temporal and Geographical Shifts in Genotype," J. Antimicrob. Chemother., vol. 72, no. 8, pp. 2145-2155, 2017.
  8. K. Bush and M. J. Macielag, "New Beta-Lactam Antibiotics and Beta-Lactamase Inhibitors," Expert Opin Ther Pat, vol. 20, pp. 1277-1293, 2010.
  9. K. Bush and G. A. Jacoby, "Updated Functional Classification of Beta-Lactamases," Antimicrob. Agents Chemother., vol. 54, pp. 969-976, 2010.
  10. I. L. Camargo, H. M. Neoh, L. Cui, and K. Hiramatsu, "Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus Aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype," Antimicrob. Agents Chemother., vol. 52, pp. 4289-4299, 2008.
  11. K. C. Carroll et al., "Jawetz, Melnick and Adelbergs Medical Microbiology," 27th ed., McGraw-Hill Education, USA, 2016.
  12. M. Castanheira, P. J. Simner, and P. A. Bradford, "Extended-Spectrum Beta-Lactamases: An Update on Their Characteristics, Epidemiology and Detection," JAC Antimicrob Resist., vol. 2, no. 3, 2021. https://doi.org/10.1093/jacamr/dlab092
  13. E. Chika et al., "Phenotypic Detection of Metallo-Beta-Lactamase and AmpC Enzymes Among Abattoir Isolates of Escherichia coli and Klebsiella Species in Abakaliki, Nigeria," Trends in Medicine, vol. 18, no. 1, 2018.
  14. M. Dehshiri et al., "The Frequency of Klebsiella Pneumonia Encoding Genes for CTX-M, TEM-1, and SHV-1 Extended-Spectrum Beta-Lactamases Enzymes Isolated from Urinary Tract Infection," Ann. Clin. Microbiol. Antimicrob., 2018.
  15. M. V. Edelstein et al., "Spread of Extensively Resistant VIM-2-Positive ST235 Pseudomonas Aeruginosa in Belarus, Kazakhstan, and Russia: A Longitudinal Epidemiological and Clinical Study," Lancet Infect Dis, 2013.
  16. A. El Salabi et al., "Genetic and Biochemical Characterization of a Novel Metallo-Beta-Lactamase, TMB-1, from an Achromobacter Xylosoxidans Strain Isolated in Tripoli, Libya," Antimicrob. Agents Chemother., 2012.
  17. R. W. Finberg and R. Guharoy, "Monobactams," in Clinical Use of Anti-Infective Agents, Springer, New York, 2012.
  18. M. L. Grayson, "Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs," Hodder Arnold, London, 2010.
  19. A. Hamprecht et al., "Detection of the Carbapenemase GIM-1 in Enterobacter Cloacae in Germany," J Antimicrob Chemother., 2013.
  20. D. P. Kateete et al., "Carbapenem Resistant Pseudomonas Aeruginosa and Acinetobacter Baumannii at Mulago Hospital in Kampala, Uganda (2007-2009)," 2016.
  21. D. T. King, S. Sobhanifar, and N. C. J. Strynadka, "The Mechanisms of Resistance to Beta-Lactam Antibiotics," in Handbook of Antimicrobial Resistance, Springer: New York, NY USA, 2017.
  22. B. Kocsis and D. Szabó, "Antibiotic Resistance Mechanisms in Enterobacteriaceae," in Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, A Méndez-Vilas, Ed., Formatex Research Center, Spain, 2013.
  23. W. Levinson, "Antimicrobial Drugs: Mechanism of Action," in Review of Medical Microbiology and Immunology, McGraw-Hill Education, 2016.
  24. L. K. Logan and R. A. Weinstein, "The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace," J Infect Dis, vol. 215, S28-S36, 2017.
  25. C. MacDougall, "Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics," in Goodman and Gilman's Pharmacologic Basis of Therapies, 13th ed., McGraw-Hill Education, 2018.
  26. M. F. A. Marjani, "Occurrence of ESBL and MBL Acinetobacter Baumannii," International Journal of Current Research, 2013.
  27. S. O. Meroueh et al., "Ab Initio QM/MM Study of Class A Beta-Lactamase Acylation: Dual Participation of Glu166 and Lys73 in a Concerted Base Promotion of Ser70," J Am Chem Soc, vol. 127, 2005.
  28. E. L. Miller, "The Penicillins: A Review and Update," J Midwifery Women's Health, vol. 47, pp. 426-434, 2002.
  29. C. S. Miller et al., "Short-Read Assembly of Full-Length 16S Amplicons Reveals Bacterial Diversity in Subsurface Sediments," 2013.
  30. J. M. Munita and C. A. Arias, "Mechanisms of Antibiotic Resistance," Microbiol. Spectrum, 2016.
  31. S. D. Oliveira et al., "Mechanisms of Antibacterial Resistance: Shedding Some Light on These Obscure Processes," in Antibiotic Resistance Mechanisms and New Antimicrobial Approaches, Academic Press, an imprint of Elsevier, 2016.
  32. I. Palzkill, "Structural and Mechanistic Basis for Extended-Spectrum Drug-Resistance Mutations in Altering the Specificity of TEM, CTX-M, and KPC Beta-Lactamases," 2018.
  33. K. M. Papp-Wallace et al., "Carbapenems: Past, Present, and Future," 2011.
  34. F. J. Perez-Llarena and G. Bou, "Beta-Lactamase Inhibitors: The Story So Far," 2009.
  35. W. A. Petri, "Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics," in Goodman and Gilman's the Pharmacological Basis of Therapeutics, 11th ed., USA: McGraw Hill, pp. 1127-1152, 2006.
  36. P. Pottinger et al., "Antibacterial Agents and Resistance," in Sherris Medical Microbiology, McGraw-Hill Education, pp. 435, 437, 444, 2018.
  37. S. Rahman et al., "The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases," Biomed. Res. Int., 9519718, 2018.
  38. O. Skold, "Antibiotics and Antibiotics Resistance," John Wiley & Sons, Inc., pp. 83, 88, 2011.
  39. T. Strateva and D. Yordanov, "Pseudomonas Aeruginosa - a Phenomenon of Bacterial Resistance," J Med Microbiol, vol. 58, pp. 1133-1148, 2009.
  40. K. S. Thomson, "Extended-Spectrum-Beta-Lactamase, AmpC, and Carbapenemase Issues," J Clin Microbiol, vol. 48, pp. 1019-1025, 2010. https://doi.org/10.1128/JCM.00219-10
  41. C. Tooke et al., "Beta-Lactamases and Beta-Lactamase Inhibitors in the 21st Century," Journal of Molecular Biology, 2019. https://doi.org/10.1016/j.jmb.2019.04.002
  42. G. Wang et al., "CTX-M Beta-Lactamase-Producing Klebsiella Pneumonia in Suburban New York, New York, USA," Emerging Infectious Diseases, vol. 19, no. 11, pp. 1803, 2013. DOI: http://dx.doi.org/10.3201.1911.121470
  43. R. Wax et al., "Bacterial Resistance to Antimicrobials," Taylor & Francis Group, LLC, 2nd ed., pp. 122, 114, 2008.
  44. A. F. Wendel et al., "Genetic Characterization and Emergence of the Metallo-Beta-Lactamase GIM-1 in Pseudomonas spp. and Enterobacteriaceae During a Long-Term Outbreak," Antimicrob. Agents Chemother., vol. 57, pp. 5162-5165, 2013
  45. U. U. Zango, M. Ibrahim, and S. A. A. Shawai, "A Review on Beta-Lactam Antibiotic Drug Resistance," MOJ Drug Des Develop Ther., vol. 3, no. 2, pp. 52-58, 2019. DOI: 10.15406/mojddt.2019.03.00080
  46. G. G. Zhanel, R. Love, and H. Adam, "Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens," 2015.

Downloads

Download data is not yet available.